{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:25:56Z","timestamp":1767713156744},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,18]]},"DOI":"10.7759\/cureus.64863","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T23:05:03Z","timestamp":1721343903000},"source":"Crossref","is-referenced-by-count":2,"title":["Recurrent Merkel Cell Carcinoma Following COVID-19 Treatment"],"prefix":"10.7759","author":[{"given":"Hirofumi","family":"Kawamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuko","family":"Saito-Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(04)01593-1","article-title":"Merkel-cell carcinoma of the skin","volume":"5","author":"Poulsen M","year":"2004","unstructured":"Poulsen M. Merkel-cell carcinoma of the skin. Lancet Oncol. 2004, 5:593-9. 10.1016\/S1470-2045(04)01593-1","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.2.588","article-title":"Merkel cell carcinoma","volume":"20","author":"Goessling W","year":"2002","unstructured":"Goessling W, McKee PH, Mayer RJ. Merkel cell carcinoma. J Clin Oncol. 2002, 20:588-98. 10.1200\/JCO.2002.20.2.588","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2021.198464","article-title":"Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism","volume":"301","author":"Policard M","year":"2021","unstructured":"Policard M, Jain S, Rego S, Dakshanamurthy S. Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism. Virus Res. 2021, 301:198464. 10.1016\/j.virusres.2021.198464","journal-title":"Virus Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/dc.24882","article-title":"Merkel cell carcinoma presenting as a malignant pleural effusion post-COVID-19 hospitalization: a case report and literature review","volume":"50","author":"Lanceta J","year":"2022","unstructured":"Lanceta J, Toprak M, Rosca OC. Merkel cell carcinoma presenting as a malignant pleural effusion post-COVID-19 hospitalization: a case report and literature review. Diagn Cytopathol. 2022, 50:E37-41. 10.1002\/dc.24882","journal-title":"Diagn Cytopathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"Hadjadj J","year":"2020","unstructured":"Hadjadj J, Yatim N, Barnabei L, et al.. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020, 369:718-24. 10.1126\/science.abc6027","journal-title":"Science"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-020-00633-7","article-title":"An aberrant STAT pathway is central to COVID-19","volume":"27","author":"Matsuyama T","year":"2020","unstructured":"Matsuyama T, Kubli SP, Yoshinaga SK, Pfeffer K, Mak TW. An aberrant STAT pathway is central to COVID-19. Cell Death Differ. 2020, 27:3209-25. 10.1038\/s41418-020-00633-7","journal-title":"Cell Death Differ"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01518","article-title":"Targeting the NLRP3 inflammasome in severe COVID-19","volume":"11","author":"Freeman TL","year":"2020","unstructured":"Freeman TL, Swartz TH. Targeting the NLRP3 inflammasome in severe COVID-19. Front Immunol. 2020, 11:1518. 10.3389\/fimmu.2020.01518","journal-title":"Front Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/srep36107","article-title":"Targeting inflammasome\/IL-1 pathways for cancer immunotherapy","volume":"6","author":"Guo B","year":"2016","unstructured":"Guo B, Fu S, Zhang J, Liu B, Li Z. Targeting inflammasome\/IL-1 pathways for cancer immunotherapy. Sci Rep. 2016, 6:36107. 10.1038\/srep36107","journal-title":"Sci Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2024202118","article-title":"The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-\u0399","volume":"118","author":"Zhang Y","year":"2021","unstructured":"Zhang Y, Chen Y, Li Y, et al.. The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-\u0399. Proc Natl Acad Sci U S A. 2021, 118:10.1073\/pnas.2024202118","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2015.154","article-title":"Next generation sequencing of cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation","volume":"29","author":"Harms PW","year":"2016","unstructured":"Harms PW, Collie AM, Hovelson DH, et al.. Next generation sequencing of cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation. Mod Pathol. 2016, 29:240-8. 10.1038\/modpathol.2015.154","journal-title":"Mod Pathol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.42188","article-title":"Merkel cell carcinoma of the left cheek with testicular metastasis: an uncommon occurrence","volume":"15","author":"Suthar PP","year":"2023","unstructured":"Suthar PP, Marathu KK, Singh JS, et al.. Merkel cell carcinoma of the left cheek with testicular metastasis: an uncommon occurrence. Cureus. 2023, 15:e42188. 10.7759\/cureus.42188","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13151","article-title":"Onset of Kaposi sarcoma and Merkel cell carcinoma during low-dose steroid therapy for rheumatic polymyalgia","volume":"42","author":"Brambilla L","year":"2017","unstructured":"Brambilla L, Esposito L, Nazzaro G, Tourlaki A. Onset of Kaposi sarcoma and Merkel cell carcinoma during low-dose steroid therapy for rheumatic polymyalgia. Clin Exp Dermatol. 2017, 42:702-4. 10.1111\/ced.13151","journal-title":"Clin Exp Dermatol"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.1001\/archderm.1991.04510010118015","article-title":"Spontaneous regression in Merkel cell (neuroendocrine) carcinoma of the skin","volume":"127","author":"Kayashima K","year":"1991","unstructured":"Kayashima K, Ono T, Johno M, Kojo Y, Yamashita N, Matsunaga W. Spontaneous regression in Merkel cell (neuroendocrine) carcinoma of the skin. Arch Dermatol. 1991, 127:550-3.","journal-title":"Arch Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-024-01405-0","article-title":"Efficacy and safety of glucocorticoids in the treatment of COVID-19: a systematic review and meta-analysis of RCTs","volume":"24","author":"Ye X","year":"2024","unstructured":"Ye X, Li Y, Luo F, et al.. Efficacy and safety of glucocorticoids in the treatment of COVID-19: a systematic review and meta-analysis of RCTs. Clin Exp Med. 2024, 24:157. 10.1007\/s10238-024-01405-0","journal-title":"Clin Exp Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta P","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020, 395:1033-4. 10.1016\/S0140-6736(20)30628-0","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1125246","article-title":"The development of COVID-19 treatment","volume":"14","author":"Yuan Y","year":"2023","unstructured":"Yuan Y, Jiao B, Qu L, Yang D, Liu R. The development of COVID-19 treatment. Front Immunol. 2023, 14:1125246. 10.3389\/fimmu.2023.1125246","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2284","article-title":"Post-transplant Merkel cell carcinoma","volume":"96","author":"Koljonen V","year":"2016","unstructured":"Koljonen V, Sahi H, B\u00f6hling T, M\u00e4kisalo H. Post-transplant Merkel cell carcinoma. Acta Derm Venereol. 2016, 96:442-7. 10.2340\/00015555-2284","journal-title":"Acta Derm Venereol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2022.04.005","article-title":"Skin cancers under Janus kinase inhibitors: a World Health Organization drug safety database analysis","volume":"77","author":"Jalles C","year":"2022","unstructured":"Jalles C, Lepelley M, Mouret S, Charles J, Leccia MT, Trabelsi S. Skin cancers under Janus kinase inhibitors: a World Health Organization drug safety database analysis. Therapie. 2022, 77:649-56. 10.1016\/j.therap.2022.04.005","journal-title":"Therapie"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2021.10.005","article-title":"Cancer and Covid-19: collectively catastrophic","volume":"63","author":"du Plessis M","year":"2022","unstructured":"du Plessis M, Fourie C, Riedemann J, de Villiers WJ, Engelbrecht AM. Cancer and Covid-19: collectively catastrophic. Cytokine Growth Factor Rev. 2022, 63:78-89. 10.1016\/j.cytogfr.2021.10.005","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.928390","article-title":"The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy","volume":"12","author":"Bruera S","year":"2022","unstructured":"Bruera S, Suarez-Almazor ME. The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy. Front Oncol. 2022, 12:928390. 10.3389\/fonc.2022.928390","journal-title":"Front Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/266546-recurrent-merkel-cell-carcinoma-following-covid-19-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T23:05:07Z","timestamp":1721343907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/266546-recurrent-merkel-cell-carcinoma-following-covid-19-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.64863","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,18]]}}}